A longitudinal study to estimate adverse events following two doses of COVID-19 vaccination

Autor: Saurabh Bobdey, Rajesh Sahu, Arun Kumar Yadav, S K Kaushik, K S Sreekanth, Niharika Nagari, Kunal Koundinya
Jazyk: angličtina
Rok vydání: 2022
Předmět:
Zdroj: Medical Journal of Dr. D.Y. Patil Vidyapeeth, Vol 15, Iss 8, Pp 334-338 (2022)
Druh dokumentu: article
ISSN: 2589-8302
2589-8310
DOI: 10.4103/mjdrdypu.mjdrdypu_722_21
Popis: Background: On March 30, 2020, coronavirus disease 19 was declared pandemic and many countries of the world started working on the development of vaccine soon after China released the genetic structure of severe acute respiratory syndrome coronavirus 2. Drugs Controller General of India on January 3, 2021, accorded emergency use authorization to Oxford-AstraZeneca's ChAdOx1 nCoV-19 vaccine and vaccination drive commenced in India on January 16, 2021. The present study was conducted to determine the incidence adverse event following immunization (AEFI) among recipients of the first and second dose of the vaccine. Materials and Methods: A longitudinal descriptive study was conducted among 2529 vaccine beneficiaries who were asked about the side effects at 24 and 72 h after the first dose and second dose of vaccination with ChAdOx1 nCoV-19 vaccine. Passive surveillance was also done for 4 months. Results: AEFI was reported in 27.59%, 38.4%, and 19.96% of vaccines after both doses, first dose, and second dose, respectively. 14% did not report any AEFI with either dose of vaccine. Younger people had higher rates of AEFIs with both the doses. Pain at injection site and fever
Databáze: Directory of Open Access Journals
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje